<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898283</url>
  </required_header>
  <id_info>
    <org_study_id>DMV02-SIT-026</org_study_id>
    <nct_id>NCT04898283</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.</brief_title>
  <official_title>A RDPC, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of SCIT in Patients With Rhinitis With or Without Mild to Moderate Asthma Sensitized to Cupressaceae and Grasses.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmunotek S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inmunotek S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to&#xD;
      Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis With&#xD;
      or Without Mild to Moderate Asthma Sensitized to cupressaceae and grasses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, multicenter, parallel, placebo controlled study. It includes 150 subjects&#xD;
      sensitised to cupressaceae and grass pollen, from 14 to 65 years of age. Medication treatment&#xD;
      during 1 year. The main outcome: CSMS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, multicentre, parallel-group study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>During the trial, both the investigator and the included subjects will be unaware of the treatment each subject is receiving.&#xD;
The person in charge of data analysis will also not know the treatment assigned to each subject until the database has been closed.&#xD;
So that neither the subject nor the investigator knows what treatment each subject is receiving, all the trial medication is identical in terms of outer packaging and appearance.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CSMS: Combined Symptoms and Medication Score, asthma and rhinitis.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the number of symptoms and the consumption of medication necessary for the control of such symptoms in asthma and rhinitis / rhinoconjunctivitis of each subject during the trial, of the groups with each other and with respect to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication free days</measure>
    <time_frame>12 months</time_frame>
    <description>Both rhinitis/rhinoconjuntivitis and asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom free days</measure>
    <time_frame>12 months</time_frame>
    <description>Both rhinitis/rhinoconjuntivitis and asthma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by T521+MG01-SIT026</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison between the beginning and end of the trial and among active groups and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life associated with asthma</measure>
    <time_frame>12 months</time_frame>
    <description>The quality of life associated with asthma will be measured following the ACQ questionnaire.&#xD;
The ACQ questionnaire consists of 6 questions (ACQ-6). In questions 1-6, patients recall their experience during the last 7 days and answer using a scale of 7 points (from 0 = fully controlled to 6 = extremely poorly controlled). The questionnaire score is the mean of the 6 responses (ACQ-6).&#xD;
The interpretation of the scores is as follows:&#xD;
Less than or equal to 0.75: Adequate control of asthma From 0.75 to 1.50: Partially controlled asthma More than 1.50: Inadequate asthma control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS</measure>
    <time_frame>12 months</time_frame>
    <description>Visual Analogue Scale in which the subject has to indicate in a straight line of 10cm how he/she feels regarding to his allergy symptoms. Being left side (0) = very bad and right side (10) = very well</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthmatic exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>Time elapsed until the first appearance of asthmatic exacerbations, number, duration and severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health resource consumption</measure>
    <time_frame>12 months</time_frame>
    <description>Counting the Health resource consumption: visits to specialists, telephone calls, test and analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life associated with rhinitis</measure>
    <time_frame>12 months</time_frame>
    <description>The quality of life associated with rhinitis will be measured following the test ESPRINT-15.&#xD;
The scoring of the questionnaire will be carried out as follows: The global sum of the scores (ranging from &quot;0 = nothing has bothered me&quot; to &quot;6 = it has bothered me a lot&quot;) of the 14 items plus the score given in the general questionnaire (ranging from &quot;0 = Excellent&quot; to &quot;4 = Bad&quot;). This sum is divided by the total number of items (15 items).&#xD;
The interpretation of the scores is between 0 (low impact) and 6 (high impact).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Rhinitis, Allergic</condition>
  <condition>Rhinoconjunctivitis</condition>
  <condition>Asthma, Allergic</condition>
  <arm_group>
    <arm_group_label>10,000 MG01 + 10,000 T521</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30,000 MG01 + 10,000 T521</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo subcutaneous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The same solution and presentation as the active treatment, but without active ingredients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10,000 MG01 +10,000 T521</intervention_name>
    <description>Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupresaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections</description>
    <arm_group_label>10,000 MG01 + 10,000 T521</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>30,000 MG01 +10,000 T521</intervention_name>
    <description>Purified allergen extract polymerized with glutaraldehyde, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupresaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections.</description>
    <arm_group_label>30,000 MG01 + 10,000 T521</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo subcutaneous</intervention_name>
    <description>The same solution and presentation as the active treatment, but without active ingredients</description>
    <arm_group_label>Placebo subcutaneous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent.&#xD;
&#xD;
          2. Aged between 14 and 65, both genders&#xD;
&#xD;
          3. Positive suggestive clinical history of intermittent or persistent moderate to severe&#xD;
             rhinitis /rhinoconjunctivitis, with or without moderate intermittent or persistent&#xD;
             asthma,according to GEMA 5.0, due to grass and cupressaceae pollen.&#xD;
&#xD;
          4. Subjects with a positive skin prick-test (wheal sixe &gt;5 mm diameter). The positive and&#xD;
             negative control of the test should give consistent results and whose determination&#xD;
             does not exceed 1 year prior to the baseline visit.&#xD;
&#xD;
          5. Specific immunoglobulin E ≥ class 3 , against grass and cupressaceae pollen&#xD;
             (InmunoCAP® o Immulite) and whose determination does not exceed 1 year prior to the&#xD;
             inclusion visit.&#xD;
&#xD;
          6. Women of childbearing age (from menarche) must present a urine pregnancy test with a&#xD;
             negative result at the time of joining the trial.&#xD;
&#xD;
          7. Women of childbearing potential, and men participating in the trial, should commit to&#xD;
             using an appropriate method of contraception. Medically acceptable methods of&#xD;
             contraception are intrauterine devices placed at least 3 months in advance, surgical&#xD;
             sterilization (for example, tubal ligation), barrier methods, or the use of oral&#xD;
             contraceptives.&#xD;
&#xD;
          8. Subjects with asthma must be diagnosed according to the GEMA 5.0 guideline.&#xD;
&#xD;
          9. Subjects capable of complying with the dosing regimen.&#xD;
&#xD;
         10. Subjects who own a smartphone for symptom registration and medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects polisensitised to other aeroallergens but sensitisation to epithelia with&#xD;
             exposure and occasional symptoms or sensitisation to pollen noncoseasonal with&#xD;
             cupressus or grasses.&#xD;
&#xD;
          2. Subjects who have received prior immunotherapy in the preceding 5 years for any of the&#xD;
             allergens tested or a cross-reactive allergen or are currently receiving immunotherapy&#xD;
             with any allergen.&#xD;
&#xD;
          3. Subjects in which immunotherapy may be subject to an absolute general contraindication&#xD;
             according to the criteria of the Immunotherapy Committee of the Spanish Society of&#xD;
             Allergy and Clinical Immunology and the European Allergy and Clinical Immunology&#xD;
             Immunotherapy Subcommittee.&#xD;
&#xD;
          4. Subjects have not granted written informed consent.&#xD;
&#xD;
          5. Subjects with severe or uncontrolled intermittent or persistent asthma, with an FEV1&#xD;
             &lt;70% with respect to the reference value despite adequate pharmacological treatment at&#xD;
             the time of inclusion in the trial. Likewise, subjects with intermittent or persistent&#xD;
             rhinitis / rhinoconjunctivitis with severe symptoms in which the suspension of oral or&#xD;
             systemic antihistamine treatment is contraindicated.&#xD;
&#xD;
          6. Subjects who have previously had a severe secondary reaction during the prick test&#xD;
             diagnostic skin test.&#xD;
&#xD;
          7. Subjects treated with beta-blockers.&#xD;
&#xD;
          8. Clinically unstable subjects at the time of inclusion in the trial (acute asthmatic&#xD;
             exacerbation, respiratory infection, febrile process, acute urticaria, etc.).&#xD;
&#xD;
          9. Subjects with active chronic urticaria, severe dermographism, severe atopic&#xD;
             dermatitis, sunburn, active psoriasis with lesions in areas where skin tests will be&#xD;
             performed, or a history of hereditary angioedema.&#xD;
&#xD;
         10. Subjects who have any pathology in which adrenaline administration is contraindicated&#xD;
             (hyperthyroidism, HTN, heart disease, etc.).&#xD;
&#xD;
         11. Subjects with any other disease not related to moderate rhinoconjunctivitis or asthma,&#xD;
             but potentially serious and that may interfere with treatment and follow-up (epilepsy,&#xD;
             psychomotor disorder, uncontrolled diabetes, malformations, multioperated patients,&#xD;
             kidney disease,).&#xD;
&#xD;
         12. Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a&#xD;
             diagnosis of immunodeficiencies.&#xD;
&#xD;
         13. Subject whose condition prevents from offering cooperation and/ or who has severe&#xD;
             psychiatric disorders.&#xD;
&#xD;
         14. Subjects with a known allergy to components of the investigational medicinal product&#xD;
             other than the allergen.&#xD;
&#xD;
         15. Subjects with lower respiratory diseases other than asthma such as emphysema or&#xD;
             bronchiectasis.&#xD;
&#xD;
         16. Subjects who are direct relatives of the researchers.&#xD;
&#xD;
         17. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Carretero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Burgos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Carretero, MD</last_name>
    <phone>947 28 18 00</phone>
    <email>pcarreteroa@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miguel Casanovas, MD PhD</last_name>
    <phone>916510010</phone>
    <email>mcasanovas@inmunotek.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedt de Tarancon</name>
      <address>
        <city>Tarancon</city>
        <state>Cuenca</state>
        <zip>16400</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Moreno Fernández, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital U. Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mª Dolores Alonso Díaz de Durana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital Sant Pere Claver</name>
      <address>
        <city>Barcelona</city>
        <zip>08004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helena Hermida Clarena, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica privada Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Aragoneses Gilsanz, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Carretero, MD</last_name>
      <phone>947 28 18 00</phone>
    </contact>
    <investigator>
      <last_name>Pedro Carretero Anibarro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalia Sofía Perea Lam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Reinares Ten, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Alloza Gómez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reyes Pérez Giménez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Manzanedo Ortega, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia del Pozuelo Aparicio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica privada</name>
      <address>
        <city>León</city>
        <zip>24001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adolfo Velez Ruiz de Lobera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Subiza</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Subiza Garrido-Lestache</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Concepción Barjau Buj</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP José Marva</name>
      <address>
        <city>Madrid</city>
        <zip>28020</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Margarita Tomás Pérez</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Contreras Porta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Alberto Luna Porta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Privada</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvia de Miguel Comes, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica privada</name>
      <address>
        <city>Palencia</city>
        <zip>34002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Izaskun Leanizbarrutia De Bizkarralegorra, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica privada</name>
      <address>
        <city>Pamplona</city>
        <zip>31006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alfredo Resano Lizaldre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Teresa Gracia Bara, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignacio Jesús Dávila González, DM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Privada Soria</name>
      <address>
        <city>Soria</city>
        <zip>42002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jonatan Vicente Serrano, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Privada Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ignacio Javier Pérez-Camo Choliz, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Guzmán-Fulgencio M, Caballero R, Lara B, Mena M, Tejera M, Sastre A, Subiza JL, Fernández-Caldas E, Casanovas M. Safety of immunotherapy with glutaraldehyde modified allergen extracts in children and adults. Allergol Immunopathol (Madr). 2017 Mar - Apr;45(2):198-207. doi: 10.1016/j.aller.2016.08.008. Epub 2016 Dec 7.</citation>
    <PMID>27939406</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinitis/ Rhinoconjunctivitis</keyword>
  <keyword>Mild to moderate asthma</keyword>
  <keyword>Allergy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Grass</keyword>
  <keyword>cupressaceae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

